%0 Journal Article
%A Pouyiourou, Maria
%A Kraft, Bianca
%A Wohlfromm, Timothy
%A Stahl, Michael
%A Kubuschok, Boris
%A Löffler, Harald
%A Hacker, Ulrich T
%A Hübner, Gerdt
%A Weiss, Lena
%A Bitzer, Michael
%A Ernst, Thomas
%A Schütt, Philipp
%A Hielscher, Thomas
%A Delorme, Stefan
%A Kirchner, Martina
%A Kazdal, Daniel
%A Ball, Markus
%A Kluck, Klaus
%A Stenzinger, Albrecht
%A Bochtler, Tilmann
%A Krämer, Alwin
%T Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial.
%J Nature Communications
%V 14
%N 1
%@ 2041-1723
%C [London]
%I Nature Publishing Group UK
%M DKFZ-2023-02165
%P 6761
%D 2023
%Z #EA:A360#LA:A360#
%X Cancer of unknown primary has a dismal prognosis, especially following failure of platinum-based chemotherapy. 10-20
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37875494
%R 10.1038/s41467-023-42400-5
%U https://inrepo02.dkfz.de/record/284981